Drug – bio-affecting and body treating compositions – Lymphokine – Interleukin
Reexamination Certificate
2007-04-10
2007-04-10
O'hara, Eileen (Department: 1647)
Drug, bio-affecting and body treating compositions
Lymphokine
Interleukin
C424S085100, C514S012200, C530S351000
Reexamination Certificate
active
09980823
ABSTRACT:
The invention relates to the use of IL6RIL6 chimera in the treatment and prevention of neurological diseases and disorders.
REFERENCES:
patent: 1999/0048413 (1999-02-01), None
patent: WO 99/02552 (1999-01-01), None
Barinaga, M. Science, vol. 264, pp. 772-773, May 1994.
XP-002156155—Haggiag et al., “Induction of myelin gene expression in cell cultures by an IL6 receptor IL6 chimera”,Neuroscience Letters, 54:S19 (1999).
XP-002156153—Haggiag et al., “Induction of myelin gene expression in Schwann cell cultures by an interleukin-6 receptor-interleukin-6 chimera”,FEBS Letters, 457:200-204 (1999).
XP-000971298—Ringheim et al., “Enhancement of beta-amyloid precursor protein transcription and expression by the soluble interleukin-6 receptor/interleukin-6 complex”,Molecular Brain Research, 55:35-44 (1998).
Boschert Ursula
Chebath Judith
Pizzi Marina
Revel Michel
Spano PierFranco
Applied Research Systems ARS Holding N.V.
Browdy and Neimark PLLC
Hamud Fozia
O'hara Eileen
Yeda Research and Development Company Ltd.
LandOfFree
IL6RIL6 chimera for the treatment of neurodegenerative diseases does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with IL6RIL6 chimera for the treatment of neurodegenerative diseases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and IL6RIL6 chimera for the treatment of neurodegenerative diseases will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3753924